DODieter Oetzel

Dieter Oetzel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dieter Oetzel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey

    by Rami A El Shafie, Dorothea Weber, Nina Bougatf, Tanja Sprave, Dieter Oetzel, Peter E Huber, Jürgen Debus, Nils H Nicolay

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Consumer electronics and web-enabled mobile devices play an increasing role in patient care and their use in the oncologic sector opens up promising possibilities in the fields of supportive cancer care and systematic patient follow-up. Objective: The present survey aimed to assess acceptance and possible benefits of a mobile application-based concept for supportive care of cancer patients undergoing radiation therapy. Methods: 975 patients presenting for radiation therapy (RT) due to breast or prostate cancer were screened and 200 owned a smartphone and consented to participating in the survey. Patients were requested to complete a questionnaire covering habits of smartphone usage, technical knowledge and abilities, readiness to use a mobile application (MA) within the context of RT, possible features of the MA and general attitude towards different aspects of oncologic treatments prior to the initiation and after completion of RT. For quantitative analysis, sum scores were calculated for all areas of interest (AOI), and results were correlated with patient characteristics. Additionally, answers were quantitatively compared before initiation and after completion of radiotherapy. Results: Median patient age was 57 years (range 27-78 years). 66.2% of the participants reported an ability to use their smartphones with little to no help. 75.8% had not used their smartphones in a medical context before; however the majority of patients showed strong interest in using a MA for supportive care during RT (73.3%) or as part of the clinical follow-up (83.4%). Patients most commonly requested functionalities regarding scheduling of appointment in the clinic (88.0%) and the collection of patient-reported outcome data regarding their illness, therapy and general well-being (67.0%). Age was identified as the most influential factor regarding patient attitude with patients <55 years significantly more inclined towards and versed in smartphone use (p=0.001). MA acceptance was significantly higher in patients showing a Karnofsky performance status <80% (p=0.014), those patients judging the main usefulness of the MA to lie in providing support in the context of therapy-related side effects (p=0.006). The overall acceptance of an MA in the context of RT surveillance ranked high at a median item sum score of 71.4/100 and was not significantly influenced by tumor stage, age, gender, treatment setting or previous radiation therapies. Conclusions: The acceptance of MAs for the surveillance and follow-up of cancer patients undergoing radiation therapy is high, and the high acceptance level will serve as a basis for future clinical trials to investigate the clinical benefit of MA-based treatment support. Introduction of MAs into the clinical routine should be regarded as an opportunity to improve and intensify supportive treatment for cancer patients.


  • Open Access

    Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey (Preprint)

    by Rami A El Shafie, Dorothea Weber, Nina Bougatf, Tanja Sprave, Dieter Oetzel, Peter E Huber, Jürgen Debus, Nils H Nicolay

    BACKGROUND Consumer electronics and Web-enabled mobile devices are playing an increasing role in patient care, and their use in the oncologic sector opens up promising possibilities in the fields of supportive cancer care and systematic patient follow-up. OBJECTIVE The objective of our study was to assess the acceptance and possible benefits of a mobile app–based concept for supportive care of cancer patients undergoing radiotherapy. METHODS In total, 975 patients presenting for radiotherapy due to breast or prostate cancer were screened; of them, 200 owned a smartphone and consented to participate in the survey. Patients were requested to complete a questionnaire at 2 time points: prior to the initiation (T0) and after the completion (T1) of radiotherapy. The questionnaire included questions about the habits of smartphone usage, technical knowledge and abilities of the participants, readiness to use a mobile app within the context of radiotherapy, possible features of the mobile app, and general attitude toward the different aspects of oncologic treatments. For quantitative analysis, sum scores were calculated for all areas of interest, and results were correlated with patient characteristics. Additionally, answers were quantitatively compared between time points T0 and T1. RESULTS Median patient age was 57 (range 27-78) years. Of the 200 participants, 131 (66.2%) reported having the ability to use their smartphones with minimal to no help and 75.8% (150/200) had not used their smartphones in a medical context before. However, 73.3% (146/200) and 83.4% (166/200) of patients showed a strong interest in using a mobile app for supportive care during radiotherapy and as part of the clinical follow-up, respectively. Patients most commonly requested functionalities regarding appointment scheduling in the clinic (176/200, 88.0%) and the collection of patient-reported outcome data regarding their illness, therapy, and general well-being (130/200, 65.0%). Age was identified as the most influential factor regarding patient attitude, with patients aged <55 years being significantly more inclined toward and versed in smartphone use (P<.001). The acceptance of mobile apps was significantly higher in patients exhibiting a Karnofsky performance index <80% (P=.01). Support in the context of therapy-related side effects was judged most important by patients with poor clinical performance (P=.006). The overall acceptance of mobile apps in the context of radiotherapy surveillance was high at a median item sum score of 71.4/100 and was not significantly influenced by tumor stage, age, gender, treatment setting, or previous radiotherapies. CONCLUSIONS The acceptance of mobile apps for the surveillance and follow-up of cancer patients undergoing radiotherapy is high; this high acceptance level will serve as a basis for future clinical trials investigating the clinical benefits of mobile app–based treatment support. Introduction of mobile apps into the clinical routine should be considered as an opportunity to improve and intensify supportive treatment for cancer patients.

  • Open Access

    Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial

    by Rami A El Shafie, Nina Bougatf, Tanja Sprave, Dorothea Weber, Dieter Oetzel, Timo Machmer, Peter E Huber, Jürgen Debus, Nils H Nicolay

    The increasing role of consumer electronics and Web-enabled mobile devices in the medical sector opens up promising possibilities for integrating novel technical solutions into therapy and patient support for oncologic illnesses. A recent survey carried out at Heidelberg University Hospital suggested a high acceptance among patients for an additional approach to patient care during radiotherapy based on patient-reported outcomes by a dedicated mobile app. The aim of this trial (OPTIMISE-1: Oncologic Therapy Support Via Means of a Dedicated Mobile App - A Prospective Feasibility Evaluation) is to prospectively evaluate the feasibility of employing a mobile app for the systematic support of radiooncological patients throughout the course of their radiotherapy by monitoring symptoms and patient performance, and facilitating the background-exchange of relevant information between patient and physician. The present single-center, prospective, exploratory trial, conducted at Heidelberg University Hospital, assesses the feasibility of integrating an app-based approach into patient-care during radiotherapy. Patients undergoing curative radiotherapy for thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related quality of life (QoL) and symptoms, and their need to personally consult a physician by means of a mobile app during treatment. The primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. Furthermore, treatment-related patient satisfaction and health-related QoL is assessed by the Patient Satisfaction Questionnaire Short Form (PSQ-18) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires at the beginning (baseline) and end of radiotherapy, and at the first follow-up. This trial will recruit 50 patients over a period of 12 months. Follow-up will be completed after 18 months, and publication of results is planned at 24 months after trial initiation. This study will serve as a basis for future studies aiming to exploit the constant innovation in mobile medical appliances and integrate novel patient-centered concepts into patient care in the context of radiotherapy. ClinicalTrials.gov NCT03168048; https://clinicaltrials.gov/ct2/show/NCT03168048 (Archived at WebCite http://www.webcitation.org/6wtWGgi0X).


  • Open Access

    Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial

    by Rami A El Shafie, Nina Bougatf, Tanja Sprave, Dorothea Weber, Dieter Oetzel, Timo Machmer, Peter E Huber, Nils H Nicolay

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The increasing role of consumer electronics and Web-enabled mobile devices in the medical sector opens up promising possibilities for integrating novel technical solutions into therapy and patient support for oncologic illnesses. A recent survey carried out at Heidelberg University Hospital suggested a high acceptance among patients for an additional approach to patient care during radiotherapy based on patient-reported outcomes by a dedicated mobile app. Objective: The aim of this trial (OPTIMISE-1: Oncologic Therapy Support Via Means of a Dedicated Mobile App – A Prospective Feasibility Evaluation) is to prospectively evaluate the feasibility of employing a mobile app for the systematic support of radiooncological patients throughout the course of their radiotherapy by monitoring symptoms and patient performance, and facilitating the background-exchange of relevant information between patient and physician. Methods: The present single-center, prospective, exploratory trial, conducted at Heidelberg University Hospital, assesses the feasibility of integrating an app-based approach into patient-care during radiotherapy. Patients undergoing curative radiotherapy for thoracic or pelvic tumors will be surveyed regarding general performance, treatment-related quality of life (QoL) and symptoms, and their need to personally consult a physician by means of a mobile app during treatment. The primary endpoint of feasibility will be reached when 80% of the patients have successfully answered 80% of their respective questions scheduled for each treatment day. Furthermore, treatment-related patient satisfaction and health-related QoL is assessed by the Patient Satisfaction Questionnaire Short Form (PSQ-18) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires at the beginning (baseline) and end of radiotherapy, and at the first follow-up. Results: This trial will recruit 50 patients over a period of 12 months. Follow-up will be completed after 18 months, and publication of results is planned at 24 months after trial initiation. Conclusions: This study will serve as a basis for future studies aiming to exploit the constant innovation in mobile medical appliances and integrate novel patient-centered concepts into patient care in the context of radiotherapy. Trial Registration: ClinicalTrials.gov NCT03168048; https://clinicaltrials.gov/ct2/show/NCT03168048 (Archived at WebCite http://www.webcitation.org/6wtWGgi0X)

  • Irradiation for Inhibition of Endothelial Cell Growth in vitro

    by A.M. Joussen, F.E. Kruse, D. Oetzel, H.E. Voelcker

    The clinical effect of ionising radiation on ocular neovascularisations is controversial, not only because of the variety of treatment modalities. The aim of our study was to investigate an experimental model which allows to evaluate radiation parameters and to study the mechanism of the inhibitory effect on neoangiogenesis. In vitro experiments were performed using human umbilical vein endothelial cells and human corneal keratocytes. The cells were irradiated with different doses of photon beam radiation and counted daily after treatment. Cell cultures confirmed the efficiency of irradiation in inhibiting proliferation of vascular endothelial cells. Radiosensitivity was shown to be higher in vascular endothelial cells than in corneal stromal keratocytes. This might be helpful in investigating therapy parameters for treating ocular neovascularisations, as well as underlying mechanisms.